In a recent study, we demonstrated that the FDA‐approved anti‐fibrotic agent nintedanib inhibited TGFα‐induced pulmonary fibrosis by limiting both fibroproliferation and myofibroblast survival (Kasam et al, 2019). Here, TGFA is linked to pulmonary fibrosis.